The European Medicines Agency (EMA) has received an application from Johnson & Johnson's Janssen Pharmaceutical Companies for the approval of Imbruvica (ibrutinib) in combination with rituximab as first-line treatment in earlier untreated chronic lymphocytic leukaemia (CLL), it was reported yesterday.
The product is already approved in Europe for CLL as a monotherapy or in combination with obinutuzumab in patients who were earlier untreated for their condition. It is also approved in Europe as a monotherapy or in combination with bendamustine and rituximab for the treatment of the same disease in adults who have undergone around one prior therapy.
It is a Bruton's tyrosine kinase inhibitor that blocks the BTK protein, whose signalling is needed by certain cancer cells to multiply and propagate. Janssen is now seeking further expansion of the drug's label and has therefore submitted a Type II variation application to the regulator based on the findings of phase 3 E1912 trial. The late-stage trial held in the US evaluated 529 patients having earlier untreated CLL, aged 70 years or younger.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients